Vanda Pharmaceuticals (VNDA) Gross Profit (2010 - 2026)

Vanda Pharmaceuticals' Gross Profit history runs 14 years deep, the most recent figure standing at $48.6 million for Q1 2026.

• In Q1 2026, Gross Profit rose 4.38% year-over-year to $48.6 million; the TTM figure through Mar 2026 stood at $205.1 million (up 7.97% YoY), while the FY2025 annual figure was $203.1 million, up 8.32% from the prior year.
• Gross Profit came in at $48.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $53.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $59.0 million in Q3 2022 to a low of $35.8 million in Q3 2023.
• A 5-year average of $49.8 million and a median of $49.9 million in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit slumped 39.4% in 2023 and rose 26.15% in 2024, its largest moves.
• Vanda Pharmaceuticals' Gross Profit stood at $58.2 million in 2022, then dropped by 28.21% to $41.8 million in 2023, then gained by 21.01% to $50.6 million in 2024, then advanced by 5.51% to $53.4 million in 2025, then retreated by 9.04% to $48.6 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $48.6 million, $53.4 million, and $53.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison